Last updated on December 2018

A Phase 2 Study of SP-02L in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)


Brief description of study

This study is a phase 2 multinational, multicenter, single-arm, open-label, non-randomized study to evaluate the efficacy and safety of SP-02L monotherapy in relapsed or refractory patients with peripheral T-cell lymphoma.

Clinical Study Identifier: NCT02653976

Find a site near you

Start Over

Solasia Pharma

Hong Kong, Hong Kong
  Connect »

Solasia Pharma

Yoshida-gun, Japan
  Connect »

Solasia Pharma

Goyang-si, Korea, Republic of
  Connect »

Solasia Pharma

Hwasun-gun, Korea, Republic of
  Connect »

Solasia Pharma

Gangnam-gu, Korea, Republic of
  Connect »

Solasia Pharma

Nowon-gu, Korea, Republic of
  Connect »

Solasia Pharma

Seodaemun-gu, Korea, Republic of
  Connect »

Solasia Pharma

Songpa-gu, Korea, Republic of
  Connect »

Solasia Pharma

Zhongzheng, Taiwan
  Connect »

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Volunteer Sign-up

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.